Abstract: Objective： To study the clinical characteristics, diagnosis and treatment of ankylosing spondylitis(AS) complicated with uveitis, and improve the understanding of this disease. Methods： A retrospective analysis of clinical data was made among 301 patients with AS, who visited outpatient and inpatient Department of Rheumatism and Immunology in the Clinical Medical College of Yangzhou University in the past three years. Patients of AS complicated with uveitis and not with uveitis were defined as the uveitis group and the non-uveitis group, and the data were analyzed statistically. Results： There were 301 patients, including 218 males and 83 females, and the ratio of male to female was about 2.6∶1. Thirty-six cases had uveitis at the moment or had ever had it before (11.96%). Gender (P=0.119), age (P=0.563), HLA-B₂₇ positive rate (P=1.000) and disease activity showed no significant difference between the two groups. And the average duration of the uveitis group (7.84±7.45 years) was longer than that of the non-uveitis group (4.14±4.43 years, P=0.006). The proportion of patients with CD25 elevated was higher in the uveitis group (55.56%) than that of the non-uveitis group (36.60%, P=0.029). The Bath Ankylosing spondylitis functional index (BASFI) score of the uveitis group (2.29±2.36) was significantly higher than that of the non-uveitis group (0.96±1.53, P=0.003). In treatment, the biological agent utilization rate of the uveitis group (41.67%) was significantly higher than that of the non-uveitis group (24.53%, P=0.029). Conclusions： The incidence of uveitis in AS patients was correlated with the duration. There were more patients with elevated CD25 level in the uveitis group, suggesting that CD25 might be associated with uveitis. The AS patients with uveitis are more likely to have impaired physical function and peripheral joint involvement. If uveitis emerges in the course of AS, active local and systemic treatment is needed. If the effect is not good, the use of biological agents may be recommended.